Schwimmer Christine, Rak Malgorzata, Lefebvre-Legendre Linnka, Duvezin-Caubet Stéphane, Plane Guillaume, di Rago Jean-Paul
IBGC-CNRS/Université Bordeaux 2, Bordeaux, France.
Biotechnol J. 2006 Mar;1(3):270-81. doi: 10.1002/biot.200500053.
Mitochondrial diseases are rare diseases most often linked to energy in the form of ATP-depletion. The high number of nuclear- and mitochondrial-DNA-encoded proteins (>500), required for ATP production and other crucial mitochondrial functions such as NADH re-oxidation, explains the increasing number of reported disorders. In recent years, yeast has revealed to be a powerful model to identify responsible genes, to study primary effects of pathogenic mutations and to determine the molecular mechanisms leading to mitochondrial disorders. However, the clinical management of patients with mitochondrial disorders is still essentially supportive. Here we review some of the most fruitful yeast mitochondrial disorder models and propose to subject these models to highthroughput chemical library screening to prospect new therapeutic drugs against mitochondrial diseases.
线粒体疾病是罕见疾病,大多与以ATP耗竭形式存在的能量相关。ATP生成以及其他关键线粒体功能(如NADH再氧化)所需的大量核DNA和线粒体DNA编码蛋白(>500种),解释了报告的疾病数量不断增加的原因。近年来,酵母已成为一种强大的模型,可用于鉴定致病基因、研究致病突变的主要影响以及确定导致线粒体疾病的分子机制。然而,线粒体疾病患者的临床管理本质上仍为支持性治疗。在此,我们综述了一些最有成效的酵母线粒体疾病模型,并建议对这些模型进行高通量化学文库筛选,以探寻针对线粒体疾病的新型治疗药物。